1
=
-
DexCom, Inc.
As of May 21, 2026 at 10:37 UTC
Chart
About DexCom, Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Market Statistics
Trading Metrics
How to Buy DXCM
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy DXCM
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesDexCom outlined its 2030 growth strategy, projecting organic revenue growth exceeding 10% annually and targeting adjusted gross profit margins of 67-69%. The company also announced a new $1 billion share repurchase program and agreed with Elliott Investment Management to appoint two new independent directors with MedTech expertise. DexCom beat Q1 earnings expectations with adjusted EPS of 56 cents versus consensus of 47 cents.
Marc Lichtenfeld, Chief Income Strategist at the Oxford Club, identifies three stocks to sell this May: DexCom faces declining growth and competitive pressure from Abbott's FreeStyle Libre; Colgate-Palmolive offers limited upside with flat performance and valuation concerns; Oracle carries significant balance sheet risks with $250 billion in undisclosed lease commitments and projected negative free cash flow. The analysis follows the historical "sell in May and go away" pattern, where S&P 500 averages only 2% gains from May through October versus 7% from November to April.
Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-positioned to deliver significant upside potential despite trading below analyst price targets.
DexCom, a leader in continuous glucose monitoring (CGM) devices, is gaining strong analyst support with 20 Buy ratings versus 4 Sell/Hold ratings and ~40% upside potential. The company beat Q1 2026 earnings expectations with $1.2B in quarterly revenue (up 15% YoY), improved margins, and $2.4B in cash. Key catalysts include the recent G7 15-Day CGM product launch, expansion into non-insulin users via the Stelo line, and manufacturing capacity expansion driving margin improvements.
The global AI in medical imaging market is experiencing rapid growth with a projected $2.20 billion valuation in 2026 and 34.8% CAGR through 2033. Major medtech companies including Danaher, Medtronic, DexCom, and Profound Medical are making strategic acquisitions and expanding AI-powered diagnostic platforms. Hospitals are increasingly prioritizing AI clinical solutions, with 57% ranking them as top technology priorities in 2026-2027, driving demand for validated platforms with real clinical evidence.
